CD8A and neoplasm: Specifically, the current checkpoint inhibitor immunotherapy works mainly by blocking the binding between PD-L1 on the surface of tumor cells and PD-1 on the surface of CD8+ T cells [29], and CD8+ T cells were proven to be a favorable prognostic biomarker for HCC [30].